Skip to content
MarketScale
‹ Back to IndustriesHealthcare

As Omicron Variant Spreads, At-Home Tests May Not Be Home for the Holidays

Omicron is the word on everyone’s tongues this holiday season, as the latest COVID-19 variant is surging just as the country enters peak travel dates. Already, airports have seen the most traffic since before the pandemic. The Biden administration has implemented testing requirements, regardless of vaccination status, to all international travelers to help curb the…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

Omicron is the word on everyone’s tongues this holiday season, as the latest COVID-19 variant is surging just as the country enters peak travel dates. Already, airports have seen the most traffic since before the pandemic. The Biden administration has implemented testing requirements, regardless of vaccination status, to all international travelers to help curb the spread. At-home tests have fast become a popular way for people to check their COVID-status, and the industry is having to adjust quickly as variants develop.

According to Gerald Commissiong, the Chief Executive Officer of Todos Medical, some at-home tests have already been rendered ineffective as the already-existent variants have changed the sequences in the virus.

“We need to start thinking about a completely new set of tests that are able to detect different parts of the virus that do not mutate,” said Commissiong.

Todos Medical is working on their own 3CL protease test that wouldn’t rely on the ever-changing sequence of the virus to detect it.

“That may be a solution to get around a mutating virus,” he said.

Another challenge during the holiday season regarding at-home tests is the delayed delivery times for packages, which could render a test potentially useless if the tested individual later encountered someone with the virus, or if the integrity of the test degraded during the shipping process. He says increasing the number of local labs is a workaround for this situation to help lessen delivery time. Commissiong spoke highly of the vaccines, though stressed that they are designed to prevent hospitalization and death.

“If you get sick, you’re less likely to have a severe disease and potentially less likely to get long COVID,” said Commissiong.

He called this “a call to action,” considering many people who have had the virus have dealt with extended issues tasting, smelling, brain fog and even worse symptoms. Commissiong spoke of the necessity to develop a strategy in how to implement rapid tests. Without such a strategy in place, he recommends the PCR test for the holiday,

“The PCR test is really the best test if you are going to go and see people and are worried you could be carrying the disease,” said Commissiong.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly has broken ground on a $6.5 billion manufacturing facility in Houston, slated for completion around 2030. While attention has focused on scaling production of Foundayo, its oral GLP-1 treatment, the project also reflects broader U.S. efforts to rebuild domestic pharmaceutical manufacturing and highlights the supply chain challenge of forecasting demand and building capacity years in advance.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain, making it difficult to commit billions to manufacturing capacity years before demand and required output are clear.
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

NextGen Invent’s Deepak Mittal argues for scoped healthcare AI pilots with early governance

NextGen Invent’s Deepak Mittal argues that healthcare AI pilots can begin with a reliable data subset and early governance. His performance figures are vendor claims, not independently verified results.

  • 01Deepak Mittal advocates starting with a defined problem and suitable data rather than waiting for perfect organization-wide data.
  • 02Some performance figures cited in the interview (for example, preparation time and model counts) are company-reported and not independently verified in this article.
  • 03NIST’s voluntary AI Risk Management Framework provides an independent structure for governance and risk evaluation.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512